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[0001] The invention relates to the modulation of ap-
optosis in mammalian cells. More particularly, the inven-
tion provides methods for identifying novel pro-apoptotic
or anti-apoptotic cellular polypeptides, methods of
screening compounds which modulate apoptosis, and
method of detecting early events of the apoptotic proc-
ess.
[0002] Apoptosis or programmed cell death is an active
process in which cells induce their self- destruction in re-
sponse to specific cell death signals or in the absence of
cell survival signals. This active process is actually es-
sential in the normal development and homeostasis of
multicellular organisms. It is opposed to necrosis which
is cell death occurring as a result of severe injurious
changes in the environment.
[0003] Apoptosis of a cell can be characterized at least
by
- the rapid condensation of the cell with collapse of
the nucleus but preservation of membranes; or,
- cleavage of nuclear DNA at the linker regions be-
tween nucleosomes to produce fragments which can
be easily visualized by agarose gel electrophoresis
as a characteristic ladder pattern.
[0004] Various pathologies occur due to a defective or
aberrant regulation of apoptosis in the affected cells of
an organism. For example, defects that result in a de-
creased level of apoptosis in a tissue as compared to the
normal level required to maintain the steady-state of the
tissue can promote an abnormal increase of the amount
of cells in a tissue. This has been observed in various
cancers, where the formation of tumors occurs because
the cells are not dying at their normal rate. Some DNA
viruses such Epstein- Barr virus, African swine fever virus
and adenovirus, also inhibit or modulate apoptosis, there-
by repressing cell death and allowing the host cell to con-
tinue reproducing the virus.
[0005] On the contrary, a defect resulting in an in-
crease of cell death in a tissue may be associated with
degenerative disorders wherein cells are dying at a high-
er rate than they regenerate. This is observed in various
disorders, such as AIDS, senescence, and neurodegen-
erative diseases.
[0006] Compounds that modulate positively or nega-
tively apoptosis can provide means for the treatment or
the prevention of these disorders. As a consequence,
the delineation of apoptotic pathways provides targets
for the development of therapeutic agents that can be
used to modulate the response of a cell to apoptotic or
cell survival signals.
[0007] Progresses have been made in identifying ex-
tracellular, intracellular and cell surface molecules that
regulate apoptosis. Previous studies have focused on
the identification of specific cell death signals, (such as
the deprivation of growth factors, the FAS/TNF system,
genotoxic agents, glucocorticoïds...), members of the
Bcl- 2 family and ICE-type proteases. But critical steps in
apoptotic pathways remain to be identified.
[0008] Accordingly, there is still a need in identifying
the cellular mechanisms involved in apoptotic pathways,
and target for the development of therapeutic agents that
can be used to modulate cell apoptosis.
[0009] Among the different transducing agents, the
Bcl- 2 family proteins act as an intracellular checkpoint in
the apoptotic pathway. The family is divided into two func-
tional groups (médecine / sciences 97 ; 13: 384-6): the
proteins that suppress cell-death (anti-apoptotic mem-
bers such as Bcl- 2, Bcl- xL, Bcl- w, Bag-1, Mcl-1, A1) and
the proteins that promote cell death (pro- apoptotic mem-
bers such as Bim, Nix, Hzk, Bax, Bak, Bcl- xs, Bad, Bik).
The Bcl-2 family has been defined by sequence homol-
ogy based upon specific conserved motifs termed BCL-
homology regions (BH1, BH2, BH3 and BH4 domains).
BH1, BH2 and BH3 domains have been shown to be
important in homodimerization or heterodimerization and
in modulating apoptosis. Anti-apoptotic molecules have
a specific BH4 domain.
[0010] It has been proposed that the ratio of pro- ap-
optotic members to anti-apoptotic members expressed
in a cell determines whether this cell will respond to an
apoptotic signal. Indeed, pro- apoptotic and anti- apoptot-
ic members antagonized each other by forming inactive
heterodimers (Oltvai et al., 1993, Cell 74: 609-619), as
a consequence only the balance may promote or prevent
a cell to undergo apoptosis.
[0011] More recently, it has been shown that phospho-
rylation of Bcl- 2 proteins can also modulate their activity.
Indeed, different anti-apoptotic pathways are likely to be
activated by growth factors, involving phosphatidylinosi-
tol 3 kinase (Pl3K), Akt kinase and Ras activated kinases.
In particular, upon stimulation of cells with IL-3 and NGF,
the pro-apoptotic Bad protein (Bcl-XL/Bcl-2 Associated
cell Death regulator, Downward, 1999, Nature Cell Biol
1: 33-35) becomes serine phosphorylated, resulting in
association to 14-3-3 protein (Hsu et al., 1997, Mol En-
docrinol 11: 1858-1867). It was proposed that such in-
teraction facilitates the translocation of phosphorylated
Bad from the mitochondrial membrane to cytosolic com-
partments, sequestering it therein and thus, preventing
further interaction with other anti-apoptotic Bcl-2 mem-
bers (US Pat No. 5,856,445). It was further shown that
association of 14-3-3 protein to Bad is dependent upon
serine 155 phosphorylation of Bad (WO 0110888, Apop-
tosis Technology Inc., 2001).
[0012] The results disclosed in the present invention
indicate that some pro- or anti- apoptotic proteins espe-
cially of the Bcl-2 family, are regulated through a newly
identified subcellular localization that is in lipid rafts
formed in the plasma membrane. This observation offers
a way to a novel general mechanism of regulation of cell
apoptosis that may play a role in the regulation of pro- or
anti- apoptotic molecules in response to cell death or cell
survival signals.
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[0013] Localization of proteins to distinct subcellular
compartments, including membranes, is a critical event
in multiple cellular pathways. Plasma membranes of
many cell types contain microdomains commonly re-
ferred to as lipid rafts, which are biochemically distinct
from bulk plasma membranes (Brown and London, 1998,
Annu Rev Cell Dev Biol 14: 111-136). These domains
consist of dynamic assemblies of sphingolipids and cho-
lesterol. More specifically, the presence of saturated hy-
drocarbon chains in sphingolipids allows for cholesterol
to be tightly intercalated, leading to the presence of dis-
tinct liquid-ordered phases, and thereby more fluid, lipid
bilayer. Lipid rafts can be isolated by subcellular fraction-
ation and density gradient ultracentrifugation according
to methods described in Hacki et al. (Oncogene 2000
19: 2286-2295) and Millan et al. (Eur J Immunol 1998
28: 2675-3684). They can also be visualized in intact
cells by confocal microscopy using, for example, fluores-
cently labelled cholera toxin subunit B (CTx) which binds
to the ganglioside GM1 (Harder et al., 1998, J Cell Biol
141: 929-942). One key element of lipid rafts is that they
can include or exclude proteins to WO 01/48236 disclos-
es methods for identifying agents which modulate the
activity of protein kinase C theta and the pharmaceutical
use of such agents; said agents were found to inhibit the
or binding of PKC-θ with lipid rafts varying degrees.
[0014] In T cells, a number of proteins involved in signal
transduction such as IcK, Lat, copurify with lipid rafts iso-
lated on sucrose gradient. Disruption of rafts integrity by
a variety of methods inhibits early activation events, sup-
porting a critical role for these domains in the recruitment
for signalling and thus, in signal transduction from cell
surface receptors. For example, the antitumor ether lipid
1-O-octadecyl-  2-O-methyl-  rac-glycero- 3-  phospho-
choline (ET-18- OCH3; edelfosine) was shown to trigger
apoptosis via translocation of Fas to lipid rafts and sub-
sequent Fas recruitment by lipid rafts (Gajate and Mol-
linedo, Blood, 2001, 98: 3860-3863).
[0015] The present invention results from the discov-
ery of a novel mechanism of cellular regulation of the
activity of pro- or anti- apoptotic molecules in a cell by
translocation of these molecules into lipid rafts under non
apoptotic conditions such as proliferative conditions or
conditions where cells do not divide.
[0016] Indeed, the inventors have surprisingly found
that interaction of a pro- apoptotic protein, such as the
Bad protein, with rafts is an active process regulated by
cytokines or growth factors. They have also shown that
segregation of this molecule from rafts in cytokine or
growth factor deprived-cells is involved in the induction
of apoptosis and associated with raft disorganization.
[0017] The invention thus provides methods for iden-
tifying cellular polypeptides which have pro-apoptotic or
anti- apoptotic activity in a particular cell type.
[0018] The invention also provides means for screen-
ing apoptosis modulating compounds which interfere
with the newly identified mechanism of apoptosis regu-
lation. Candidate compounds in this respect may either
interfere by blocking, preventing or stimulating translo-
cation of one or several pro- or anti- apoptotic polypep-
tides in lipid rafts under non apoptotic conditions. Can-
didate compounds may in addition or alternatively inter-
fere by disrupting or reconstituting lipid rafts in a cell
which normally produce pro- or anti- apoptotic polypep-
tides located in lipid rafts under non apoptotic conditions.
According to another embodiment, candidate com-
pounds may in addition or alternatively interfere by seg-
regation of pro- or anti- apoptotic polypeptides from lipid
rafts.
[0019] The invention also provides a compound capa-
ble of modulating association of a pro- or anti-apoptotic
polypeptide with lipid rafts.
[0020] The invention also provides a compound capa-
ble of modulating transfer of a pro- or anti-apoptotic
polypeptide between a lipid raft and another cellular lo-
calization.
[0021] The invention also provides for the use of com-
pounds capable of modulating lipid rafts formation or of
modulating translocation of pro- or anti-apoptotic pro-
teins in rafts in the preparation of a medicine for the pre-
vention and/or treatment of disorders induced by or as-
sociated with a defective regulation of cell death as well
as of specific pathologies in which the death of infected
or deregulated cells may be at least art of a therapy.
[0022] Among the several advantages of the present
methods, it should be noted that the apoptotic or non
apoptotic state of a cell can be determined according to
the present methods in a relatively short period of time
by analysing lipid raft organization. In particular, there is
no need to quantify specific gene expression. The meth-
ods of the invention are thus particularly appropriate for
routine high throughput screening of apoptosis modulat-
ing compounds.
[0023] Furthermore, the invention provides methods
for detecting early events of the apoptotic process in a
cell.
[0024] A first object of the invention is a method of
screening cellular polypeptides for pro-apoptotic or anti-
apoptotic activity in a cell of a particular cell-type, said
method comprising: 
a. culturing cells of said particular cell-type under
non apoptotic conditions and culturing cells of said
particular cell-type under apoptotic conditions; and,
b. determining subcellular localisation of said cellular
polypeptides in the cultured mammalian cells;
wherein a localization of a cellular polypeptide in lipid
rafts in cells cultured under non apoptotic conditions and
a segregation of said cellular polypeptide from lipid rafts
in cells cultured under apoptotic conditions is indicative
of the pro-apoptotic or an anti-apoptotic activity of said
cellular polypeptide in said particular cell- type.
[0025] In a particular embodiment, said cultured cells
are mammalian cells.
[0026] In a preferred embodiment, the cells cultured
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under non apoptotic conditions are cultured under prolif-
erative conditions. According to the methods of the in-
vention, cells are considered to be cultured "under non
apoptotic conditions" when the proportion of cells under-
going apoptotic process in the cell culture is relatively
stable in time and does not represent more than 10%,
preferably, more than 1% of the whole cell population
(depending upon the cell-type).
[0027] In a preferred embodiment, non apoptotic con-
ditions are proliferative conditions.
[0028] On the contrary, cells are considered to be cul-
tured "under apoptotic conditions" when the proportion
of the cells undergoing apoptotic process increases dra-
matically in time to reach, after a certain period, especially
for around 24 hours, from deprivation of growth or prolif-
eration factor or by use of an apoptotic factor, more than
50% of the whole cell population.
[0029] Cells which have undergone apoptotic process
can be characterized, for example, by specific cleavage
of nuclear DNA which can be visualized on agarose gel
electrophoresis.
[0030] As used herein, the term "cellular polypeptide"
refers to any polypeptide which is produced in a cell by
gene expression. It can be a polypeptide naturally en-
coded in said cell especially by a native gene, or a
polypeptide not naturally encoded in said cell, meaning
that the gene encoding said polypeptide or a coding se-
quence derived from said identified gene has been re-
combined in the genome of the cell to obtain expression.
It can be a mutated form of a naturally occurring polypep-
tide and more specifically, a mutated form wherein the
mutation is involved in abnormal subcellular localisation
of said polypeptide under proliferative growth conditions.
[0031] As used herein, the term "lipid rafts" refers to
dynamic assemblies of sphingolipids and cholesterol in
plasma membranes forming microdomains with distinct
liquid- ordered phases, said microdomains stably retain-
ing specific structures, such as gangliosides or polypep-
tides such as Lck. Lipid rafts can be biochemically iso-
lated by subcellular fractionation and density gradient ul-
tracentrifugation according to the methods described in
Hacki et al. (Oncogene 2000 19: 2286-2295) and Millan
et al. (Eur J Immunol 1998 28: 2675-3684) and in the
examples below. They can also be visualized in intact
cells by confocal microscopy using, for example, fluores-
cently labelled cholera toxin subunit B (CTx) which binds
to the ganglioside GM1 which accumulate in lipid rafts
(Harder et al., 1998, J Cell Biol 141: 929-942). More spe-
cifically, subcellular localization of a particular polypep-
tide in lipid rafts is determined by double immunofluores-
cence using a labelled marker detecting lipid rafts and
another labelled marker detecting the polypeptide to lo-
calize. It can also be determined by analysing the pres-
ence of said polypeptide in subcellular fractions contain-
ing lipid rafts.
[0032] In a particular embodiment, the method of the
invention is appropriate to screen a polypeptide, whose
structure is known but whose function is unknown, for a
pro- or anti- apoptotic activity in a particular cell type. In
particular, the one skilled in the Art can use the method
of the invention to screen polypeptides which are sus-
pected to be involved in apoptosis regulation according
to specific features such as specific structural domains.
The screening of cellular polypeptides is however not
necessarily limited to cellular polypeptides of known
structure.
[0033] Several pro-apoptotic proteins have been iden-
tified so far, however, expression pattern of these pro-
teins may vary depending upon the cell type. The method
of screening is thus also useful in determining whether
a putative cellular polypeptide, known to be pro- or anti-
apoptotic in a certain cell-type is involved in apoptosis
modulation in another cell-type.
[0034] In a particular embodiment, the screened
polypeptides belong to the Bcl-2 family. As mentioned
hereabove, the Bcl-2 family members are characterized
by sequence homology based upon specific conserved
motifs termed BCL- homology regions (BH1, BH2, BH3
and BH4 domains). Accordingly, their subcellular locali-
sation can be determined by the use of a molecule which
specifically recognizes a BH domain. Such molecules
encompass for example monoclonal antibodies or poly-
clonal antibodies specifically recognizing a BH domain.
One example of a molecule that interacts with BH3 motif
in PP1a (Ayllon, et al. 2000. EMBO J.; 19: 2237-2246).
Examples of molecules that interact with BH4 motif are
review in Admas, J.M. and Cory, S. (1998) Science, 281,
1322). In a particular embodiment, a molecule which spe-
cifically recognizes a BH4 domain is used to screen pref-
erably for anti-apoptotic molecules. In another particular
embodiment, a molecule which specifically recognizes a
BH3 domain is used to screen for pro- or anti- apoptotic
molecules. A combination of molecules recognizing the
different BH domains can also be used, for example to
screen for pro- apoptotic molecules which have only the
BH3 domain.
[0035] The method of the invention is also appropriate
to screen novel polypeptides of the Bcl-2 family whose
structure and function are unknown at least in part, but
which can be easily isolated using molecular recognition
of their BH domain(s). As a result, in a preferred embod-
iment, said screened cellular polypeptides are first iso-
lated from biochemically isolated lipid rafts of said mam-
malian cells cultured in proliferative conditions by the use
of a molecule which specifically recognizes a BH domain.
More specifically, the polypeptides present in the isolated
lipid rafts can be separated on a gel and analysed by
Western Blot analysis using an antibody which recogniz-
es a BH domain or by similar methods of protein analysis.
The polypeptides recognized by a BH domain can be
isolated and antibodies which recognize each isolated
polypeptides can be produced according to usual meth-
ods well known in the art. The subcellular localization of
one or more of the isolated polypeptides is then deter-
mined according to the method of the invention using
such specific antibodies to screen for apoptotic activity.
5 6 













[0036] The proteins which are associated with lipid
rafts may have a transmembrane domains or have un-
dergone post- translational modifications such as myris-
toylation. In another specific embodiment, said screened
cellular polypeptides are further isolated by the use of a
molecule which specifically recognizes a mirystoylated
polypeptide.
[0037] In a preferred embodiment, the method is car-
ried out for screening cellular polypeptides of a cell type
characterized by the production of Bad protein, i.e. Bad+
cell type. According to another preferred embodiment,
the cells are characteristic of the immune system, and
most preferably are T cell lines.
[0038] Indeed, it is shown, in the examples below, that
the pro-apoptotic Bad protein is sequestered in lipid rafts
of IL-4 stimulated T-cells and segregates from rafts in IL-
4 deprived T-cells.
[0039] More specifically, it is shown in the Example
that Bad can be co- purified with lipid-rafts by subcellular
fractionation and density gradient ultracentrifugation
from cells under non-apoptotic conditions, especially un-
der proliferative conditions. These results indicate that
Bad is strongly associated with lipid rafts in cells cultured
under non apoptotic conditions such as proliferative con-
ditions.
[0040] Cellular polypeptides which physically interacts
with Bad protein in isolated lipid rafts of Bad+ cells thus
constitute preferred putative polypeptides to screen for
pro- or anti- apoptotic activity. Accordingly, in a preferred
embodiment, the screened cellular polypeptides are iso-
lated from isolated lipid rafts of Bad+ cells cultured under
proliferative conditions and are selected among the
polypeptides which interact physically with the Bad pro-
tein.
[0041] Naturally, the invention also pertains to the new-
ly identified cellular polypeptides having pro- or anti-ap-
optotic activity and their use in providing means for mod-
ulating apoptosis in cells, such as mammalian cells, ex-
pressing these polypeptides.
[0042] It is another object of the invention to provide a
method of screening compounds for their capacity to
modulate apoptosis in cells, which produce pro- or anti-
apoptotic polypeptides which are located in lipid rafts
when said cells are cultured under non apoptotic condi-
tions, said method comprising: 
a) culturing said cells in a growth medium maintain-
ing non apoptotic conditions;
b) contacting said cultured cells with a candidate
compound;
c) determining the level of one or several pro- or anti-
apoptotic polypeptides associated to lipid rafts;
d) selecting the compound which interferes with the
association of one or several pro- or anti- apoptotic
polypeptides with lipid rafts, said compound having
the capacity to modulate apoptosis.
[0043] A compound interferes with the association of
a pro- or anti- apoptotic polypeptide when it modifies said
association, including when it alters the chemical and/or
the physical nature of said association or when it provides
or influences segregation of pro- or anti-apoptotic
polypeptides from lipid rafts, or when it prevents said as-
sociation, or also when it acts on and especially promotes
disruption of lipid rafts or more generally alter constitution
of lipid rafts.
[0044] The invention further relates to a method of
screening compounds for their capacity to promote ap-
optosis in cells, said method comprising
a) culturing cells in a growth medium maintaining
non apoptotic conditions; wherein said cells produce
a pro-apoptotic protein which is located in lipid rafts
under non apoptotic conditions of said cells;
b) contacting said cultured cells with a candidate
compound; and,
c) determining the absence or the presence of lipid
rafts in said cultured cells;
d) in case of presence of lipid rafts, optionally deter-
mining the level of pro-apoptotic protein located in
the lipid rafts,
wherein the absence of lipid rafts in the plasma mem-
brane of cells incubated with said candidate compound
or if determined, the reduced level of pro-apoptotic pro-
tein in the rafts is indicative that said compound promotes
apoptosis.
[0045] The invention also relates to a method of
screening compounds for their capacity to inhibit or pre-
vent apoptosis of cells, said method comprising:
a) culturing cells in a growth medium for maintaining
non-apoptotic conditions; wherein said cells produce
a pro-apoptotic protein which is located in lipid rafts
under non apoptotic conditions;
b) contacting said cells with a candidate compound;
c) culturing cells under apoptotic conditions; and,
d) determining the absence or the presence of lipid
rafts;
e) in the case of presence of lipid rafts, optionally
determining the level of pro-apoptotic protein located
in the lipid rafts,
wherein the presence of lipid rafts in the plasma mem-
branes of cells incubated with said candidate compound
and optionally the maintained level of proapoptotic pro-
tein in the rafts is indicative that said candidate compound
inhibits or prevents apoptosis.
[0046] In a preferred embodiment, the cells are cul-
tured in a growth medium comprising at least a cytokine
or a growth factor necessary for maintaining proliferative
growth conditions and step c) of the method comprises
depriving the cells of said cytokine or growth factor nec-
essary for maintaining proliferative growth conditions.
[0047] As used herein, the term "compound" refers to
inorganic or organic chemical or biological compounds
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either natural (isolated) or synthetic, and especially en-
compass nucleic acids, proteins, polypeptides, peptides,
glycopeptides, lipids, lipoproteins and carbohydrates.
[0048] Any cells in which pro- or anti-apoptotic proteins
may be translocated in lipid rafts can be used in the meth-
ods of the invention. In a preferred embodiment of the
methods of the invention, cells are mammalian cells.
[0049] Mammalian cells which are used in the methods
of screening compounds can be any mammalian cells
whose cell survival can be controlled by a specific cy-
tokine or growth factor. In preferred embodiments of the
above methods, the cultured mammalian cells are se-
lected among those which produce the Bad protein as a
pro-apoptotic protein. More specifically, preferred mam-
malian cells which produce a Bad protein are selected
among cells characteristic of the immune system, and
more preferably among T cells.
[0050] As used herein, the term "cytokine or growth
factor" refers to any molecule which is necessary to be
present in a growth medium to prevent apoptotic process
of a cultured cell and/or to promote cell proliferation.
Known cytokines include any interleukin. Known growth
factors include the fibroblast growth factors, bFGF, aF-
GF, FGF6, the hepatocyte growth factors HGF/SF, the
epidermis growth factor, EGF and other characterized
growth factors such as IGF- 1, PDGF, LIF, VEGF, SCF,
TGFb, TNFa, NGF, BMP, neuregulin, thrombopoïetin
and growth hormone. Growth factors according to the
invention can include also, progestagenes and deriva-
tives thereof (progesterone), oestrogens and derivative
thereof (oestradiol), androgenes (testosterone), miner-
alocorticoïds and derivatives thereof (aldosterone), LH,
LH-RH, FSH et TSH hormones, T3, T4, and retinoidic
acid, calcitonine E2 and F2/alpha prostaglandins. Glu-
cocorticoïds (natural or hemisynthetic, i.e. hydrocorti-
sone, dexamethasone, prednisolone or triamcinolone),
can also be used.
[0051] Cells characteristic of the immune system can
be advantageously cultured under stimulation with an in-
terleukin for maintaining proliferative growth conditions.
In particular, IL-4, IL-2 or IL-9 interleukin can be used in
this context, or a mixture thereof.
[0052] However, any available apoptosis model can
be used to select the cell type and the factors for non
apoptotic conditions such as the growth factor or cy-
tokine, used in the methods. As used herein, the term
"apoptosis model" comprises any teaching providing a
way to control cell apoptosis in a cell culture of a specific
cell type by the use of specific factors for non apoptotic
conditions such as a specific cytokine or growth factor or
a mixture thereof. Such apoptosis models are for exam-
ple the control of IL- 4 stimulated T- cell lines, IL3 and he-
matopoietic progenitor, PC12 and CRH (corticotropin-re-
leasing hormone), HN9.10.
[0053] A candidate compound may modulate apopto-
sis by blocking or preventing the association of said pro-
or anti- apoptotic polypeptide with lipid rafts. In this con-
text, the subcellular localisation of said pro- or anti- ap-
optotic polypeptide in lipid rafts is no more observed in
cells incubated with the compound when compared to
cells not incubated with the compound, or, at least, lipid
rafts subcellular localisation of said pro- or anti-apoptotic
polypeptide is significantly reduced when compared to
cells not incubated with the compound.
[0054] It is another object of the invention to provide
compounds capable of modulating association of a pro-
or anti- apoptotic polypeptide with lipid rafts.
[0055] Some of these compounds may modulate ap-
optosis by preventing the association of a pro- or anti-
apoptotic polypeptide with lipid rafts, by promoting seg-
regation of a pro- or anti-apoptotic polypeptide from lipid
rafts or by promoting disruption of lipid rafts.
[0056] Some of these compounds may modulate ap-
optosis by preventing the segregation of a pro- or anti-
apoptotic polypeptide from lipid rafts, by promoting the
association of a pro- or anti-apoptotic polypeptide with
lipid rafts or by promoting constitution of lipid rafts.
[0057] It is another object of the invention to provide
compounds capable of modulating transfer of a pro- or
anti- apoptotic polypeptide between a lipid raft and anoth-
er cellular localization.
[0058] Some of these compounds may modulate ap-
optosis by preventing transfer of a pro- or anti-apoptotic
polypeptide from a cellular localization, other than a lipid
raft, to a lipid raft or from a lipid raft to another cellular
localization.
[0059] Some of these compounds may modulate ap-
optosis by promoting transfer of a pro- or anti- apoptotic
polypeptide from a cellular localization, other that a lipid
raft, to a lipid raft or from a lipid raft to another cellular
localization.
[0060] In a preferred embodiment, the compounds of
the invention modulating apoptosis are capable of mod-
ulating the association of a pro-apoptotic protein of Bcl-
2 family, especially Bad, with lipid rafts or transfer of said
protein between lipid rafts and another cellular localiza-
tion.
[0061] Some of said compounds may promote apop-
tosis in a Bad-producing cell by preventing association
of Bad with lipid rafts, by promoting segregation of Bad
from lipid rafts or by promoting disruption of lipid rafts.
[0062] Some of said compounds may inhibit apoptosis
in a Bad-producing cell by promoting association of Bad
with lipid rafts, by preventing segregation of Bad from
lipid rafts or by promoting constitution of lipid rafts.
[0063] In a particular embodiment, a compound of the
invention may inhibit apoptosis of a Bad-producing cell
by preventing transfer of Bad to mitochondria after Bad
segregation from lipid rafts. Such a compound may in-
teract with Bad by means of a motif similar to the lipid
raft motifs which allow association of Bad to lipid rafts.
[0064] Lipid rafts subcellular localisation of said pro-
or anti-apoptotic polypeptide can be quantified by any
quantitative analysis methods available in the art. A sig-
nificant reduction of lipid rafts subcellular localisation is
observed when the level of pro- or anti- apoptotic polypep-
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tide is reduced to at least 50%, preferably 90% in cells
incubated with the candidate compound or compared to
cells not incubated with the candidate compound.
[0065] A candidate compound may modulate apopto-
sis by blocking or preventing the segregation of said pro-
or anti- apoptotic polypeptide from lipid rafts. In this con-
text, the subcellular localisation of said pro- or anti- ap-
optotic polypeptide in lipid rafts of cells cultured under
conditions promoting pro- or anti-apoptotic protein seg-
regation (e.g., apoptotic conditions for pro-apoptotic pro-
teins) remains observed in cells incubated with the com-
pound when compared to cells not incubated with the
compound and lipid rafts subcellular localisation of said
pro- or anti-apoptotic polypeptide is significantly main-
tained when compared to cells not incubated with the
compound.
[0066] Lipid rafts subcellular localisation of said pro-
or anti-apoptotic polypeptide can be quantified by any
quantitative analysis methods available in the art. A sig-
nificant maintenance is observed when the level of pro-
or anti-apoptotic polypeptide is maintained to at least
50%, preferably 90% in cells incubated with the candi-
date compound or compared to cells not incubated with
the candidate compound or compared to cells not incu-
bated with the candidate compound.
[0067] By "determining the absence of lipid rafts", it is
understood that lipid rafts in cells incubated with the can-
didate compound are not detected, or at least, are de-
tected as traces, or are detected in a significantly reduced
level (i.e., minimum 20% less) with the methods dis-
closed in the present invention as compared with a cul-
ture of cells not incubated with the candidate compound
as a control. The proportion of lipid rafts in a cell can be
compared between the cell cultures using any quantita-
tive analysis methods available in the art. A significant
reduction of lipid rafts is observed when their proportion
is reduced from 20%, preferably is reduced to at least
50%, preferably 90% in cells incubated with the candi-
date compound to the control. For example, by confocal
microscopy analysis, the profile of fluorescence can be
quantified by image analysis of cells incubated with the
candidate compound and cells not incubated with the
candidate compound.
[0068] Similarly, by "determining the presence of lipid
rafts", it is understood that lipid rafts in cells incubated
with the candidate compound are detected in substan-
tially the same amount as compared with a culture of
cells not incubated with the candidate compound as a
control.
[0069] Methods to isolate lipid rafts have been de-
scribed below. More specifically, it is possible to isolate
lipid rafts from mammalian cells, by cell fractionating over
sucrose gradient and immunoblotting subcellular frac-
tions with markers specific for rafts in order to identify
rafts containing subcellular fractions. The presence or
the absence of lipid rafts can be thus determined in a
specific embodiment by the following steps
i) recovering the cultured cells incubated with said
compound and resuspending said cells in a buffer
appropriate for subcellular fractionation, such as gra-
dient sucrose buffer;
ii) ultracentrifugating the fractionated cells;
iii) recovering the subcellular fraction which should
contain lipid rafts; and,
iv) determining whether the recovered subcellular
fraction contains ganglioside and/or lipid raft asso-
ciated molecule(s).
[0070] As used herein, "the subcellular fraction which
should contain lipid rafts" is the subcellular fraction cor-
responding to the banded organelles of the gradient
which contains lipid rafts in a gradient obtained with cells
cultured under non apoptotic conditions. Naturally, in ap-
optotic conditions, the corresponding cell fraction will
contain much less lipid rafts.
[0071] Lipid rafts and lipid rafts subcellular localisation
of pro- or anti- apoptotic polypeptides can also be directly
visualized in intact cells by confocal microscopy using a
molecular marker which specifically binds to a raft-asso-
ciated molecule or a ganglioside.
[0072] Such preferred molecular markers are, for ex-
ample, the cholera toxin subunit B (CTx) which specifi-
cally recognizes ganglioside GM1, anti- Bad antibody or
anti- Lck antibody. More generally, any antibody directed
to any cellular polypeptide newly identified according to
the method of the invention as described above can be
used as a molecular marker specific for raft.
[0073] The invention also concerns the compounds
identified by the methods of screening.
[0074] Such compounds identified by the above meth-
ods of the invention are useful for the prevention and/or
treatment of disorders induced by or associated with a
defective regulation of cell death or of specific patholo-
gies where death of infected or deregulated cells may be
at least part of a therapy.
[0075] The invention further provides a use of a com-
pound capable of modulating lipid rafts formation, in the
preparation of a medicine for the treatment of disorders
induced by or associated with a defective regulation of
cell death.
[0076] In a preferred embodiment, said defective reg-
ulation affects cells which produce Bad protein, more
preferably, cells of the immune system and most prefer-
ably T- cells.
[0077] When said defective regulation of cell death re-
sults in an abnormal decrease of cell death, the used
compound is preferably a compound which is capable of
disrupting lipid rafts, thereby promoting apoptosis. Such
compounds are for example, methyl-β-cyclodextrin or fil-
ipin. Examples of disorders resulting in an abnormal de-
crease of cell death are cancer diseases and especially
lymphoproliferative cancers, infectious diseases and es-
pecially viral diseases, inflammatory diseases or auto-
immune diseases.
[0078] Conversely, when defective regulation of apop-
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tosis results in an abnormal increase of cell death, the
used compound is preferably a compound capable of
reconstituting lipid rafts in the plasma membrane of cells,
such as edelfosine thereby preventing apoptosis. Exam-
ples of disorders resulting in an abnormal increase of cell
death is diseases associated to senescence, neuro-de-
generative diseases, including Alzheimer disease,
ischemic cell death, wound-healing or AIDS.
[0079] The invention provides new means to detect
early events of the apoptotic process. In particular, the
invention enables to identify the apoptotic state of a cell
by determining the presence or the absence of lipid rafts.
Accordingly, another object of the invention is an in vitro
method for the detection of a defective regulation of ap-
optosis, in a sample of cells of an individual, said method
comprising determining the presence or the absence of
lipid rafts in said cells, wherein the absence of said lipid
rafts is indicative of a defective regulation of apoptosis.
[0080] Examples of methods for determining the pres-
ence or absence of lipid rafts in cells have already been
described above. In a preferred embodiment, the pres-
ence or the absence of lipid rafts is determined by de-
tecting the presence or absence of a pro-apoptotic or an
anti- apoptotic protein which is known to be located in lipid
rafts under proliferative growth conditions, such as the
Bad protein, or any other protein, and especially a cellular
polypeptide identified according to the method of the in-
vention exposed above.
[0081] In a specific embodiment, said isolated cells are
cells characteristic of the immune system of an individual
affected by a lymphoproliferative disease.
[0082] Naturally, the invention also concerns a use of
a compound appropriate for detecting the presence of
lipid rafts, in the in vitro detection method described
above.
[0083] Examples of a compound appropriate for de-
tecting the presence of lipid rafts is a compound which
specifically recognizes Bad protein, Lck protein or gan-
glioside GM1. In a specific embodiment, said compound
used in the in vitro detection method is selected among
cholera toxin subunit B (CTx), anti- Bad antibody and anti-
Lck antibody.
LEGENDS TO THE FIGURES
Figure 1. Effect of IL-4 on association of Bad to 14-3-3 
protein
[0084] Cytoplasmic extracts from 10  106 IL-4-stim-
ulated or -deprived cells were immunoprecipitated with
anti- Bad or anti- Raf antibodies and blotted with anti-
14-3-3, anti-Raf and anti- Bad. Total extracts (lane T)
were used as a positive control of 14-3-3 and Raft ex-
pression. Similar results were obtained in three inde-
pendent experiments.
Figure 2. Subcellular localization of Bad in IL- 4-stimu-
lated or -deprived cells.
[0085] A) Anti-Bad, anti-Lck (rafts), CTx- Biotin (GM1
ganglioside, rafts), anti- caspase 3 (cytosol), anti-calnex-
in (endoplasmic reticulum, ER) and anti-cytochrome C
(mitochondria) immunoblot analysis of subcellular frac-
tions from IL- 4-stimulated or -deprived cells. The frac-
tions (1 to 4) were prepared by sucrose gradient ultra-
centrifugation and tested for their purity using antibodies
against mitochondria, rafts, ER and cytosol. Nuclear frac-
tion is not shown in the blot (fraction 5). Protein loaded
per well in each gradient fraction corresponds to that of
5  106 cells. Total extracts, 30 Pg of protein. Similar
results were obtained in three independent experiments.
B) IL- 4-stimulated or -deprived cells were Triton X-100
extracted and fractionated in Optiprep flotation gradient.
Fractions were collected from the top to the bottom of
gradient and analyzed by western blot. Only the first, in-
soluble proteins (I) and the last fraction, soluble proteins
(S) are shown. Similar results were obtained in two in-
dependent experiments.
Figure 3. Rafts localization of Bad in IL-4-stimulated cells
[0086] A) IL- 4- stimulated or -deprived cells were
stained with CTx-FITC and either anti- Lck or anti- Bad
antibodies as indicated, followed by Cy3-labeled second-
ary antibody and analyzed by confocal microscopy.
Similar results were obtained in three independent ex-
periments. Single confocal sections show fluorescence
in green (FITC) and red (Cy3). B) IL-4-stimulated or -de-
prived cells were stained with anti-Bad and anti- mito-
chondria antibodies, followed by FITC- and Cy3-labeled
secondary antibodies and analyzed as above. Similar
results were obtained in three independent experiments.
Figure 4. Methyl-β-cyclodextrin (M- β-CD) treatment 
abolishes association of Bad to rafts and induces apop-
tosis.
[0087] A) IL-4-stimulated cells were serum-starved for
30 min and then treated with or without 10 mM M-β-CD
for 30 min at 37°C before incubation with CTx-FITC and
anti- Bad or anti-Lck antibodies, followed by Cy3- labeled
secondary antibody. Then, cells were analyzed by con-
focal microscopy. Similar results were obtained in two
independent experiments. Single confocal sections show
green (FITC) and red (Cy3) fluorescence. B) IL-4-stimu-
lated cells were serum- starved for 30 min and then treat-
ed with or without 10 mM M-β-CD for 30 min at 37°C,
then washed and transferred to complete medium sup-
plemented with IL-4. At different times, apoptosis was
measured. Sub G1 region of the fluorescence scale was
used to determine the percentage of cells present in the
initial step of apoptosis. Similar results were obtained in
two independent experiments. White bars, control cells;
grey bars, M-β-CD-treated cells.
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Figure 5. Effect of IL- 4 on serine phosphorylation of Bad.
[0088] A) Cytoplasmic extracts from IL- 4- stimulated or
-deprived cells were immunoprecipitated with anti- Bad
antibody and blotted with anti-Bad serine 136, 112 and
155. As internal control, the blot was developed with anti-
Bad. Positive control for serine 112 and 136 phosphor-
ylation, IL-2- stimulated cells; positive control for serine
155 phosphorylation of Bad, Bad-transfected COS cells
(C). B) Western blot from figure 2A was proved with anti-
Bad serine 136 antibody. Molecular weight of the corre-
sponding proteins is shown.
EXAMPLES
1. MATERIALS AND METHODS
1.1 Cells, lymphokines and reagents
[0089] TS1αβ is a murine T cell line that can be prop-
agated independently in IL-2, IL-4 or IL- 9 Cells were cul-
tured in RPMI-1640 as previously described (Pitton et
al., 1993, Cytokine 5, 362-371). Murine rIL-4 or super-
natant of a HeLa subline transfected with PKCRIL-4.neo
was used as a source of murine IL-4. Fluorescein isothi-
ocyanate (FITC-)-labeled cholera toxin (CTx) B subunit,
CTx-Biotin and methyl-β-cyclodextrin (M-β-CD) were ob-
tained from Sigma-Aldrich (St. Louis, MO). Cy3- and Cy2-
conjugated secondary antibodies were purchased from
Molecular Probes (Eugene, OR). Anti-mitochondria se-
rum (mito 2813; pyruvate dehydrogenase) was a gift from
Dr A. Serrano (CNB, Madrid, Spain).
1.2 Immunoprecipitation and Western blot
[0090] Cells (1  107) were IL- 4- stimulated or -de-
prived and lysed for 20 min at 4°C in lysis buffer (50 mM
Tris-HCl pH 8, 1% Nonidet P- 40, 137 mM NaCl, 1 mM
MgCl2, 1 mM CaCl2, 10% glycerol and protease inhibitor
mixture). Lysates were immunoprecipitated with the cor-
responding antibody (Calbiochem Transduction Labora-
tory). Protein A-Sepharose was added for 1 h at 4°C and,
after washing, immunoprecipitates were separated by
SDS- PAGE. Alternatively, cells were lysed in Laemmli
sample buffer and protein extracts separated by SDS-
PAGE, transferred to nitrocellulose, blocked with 5% non
fat dry milk in Tris-buffered saline (TBS, 20 mM Tris HCl
pH 7.5, 150 mM NaCl) and incubated with primary anti-
body in TBS/0.5% non fat dry milk. Membranes were
washed with 0.05% Tween 20 in TBS and incubated with
PO-conjugated secondary antibody. After washing, pro-
teins were developed using the ECL system.
1.3 Cell cycle analysis
[0091] A total of 2  105 IL-4- stimulated cells treated
with or without M-β-CD were washed, resuspended in
PBS, permeabilized with 0.1 % Nonidet P-40 and stained
with 50 Pg/ml propidium iodide (PI). At different times,
samples were analyzed using a EpicsXL flow cytometer
(Coulter, Hialeah, FL). Apoptosis was measured as the
percentage of cells in the sub-G1 region of the fluores-
cence scale having an hypodiploid DNA content. 
Cell cycle was also analyzed by annexin staining. A total
of 2  103 cells were washed with ice-cold PBS diluted
in ice-cold binding buffer and stained with annexin and
propidium iodide. Samples were maintained on ice for
10 min in the dark and then analyzed by flow cytometry.
1.4 Subcellular fractionation
[0092] Subcellular fractionation was performed as pre-
viously described (Hacki et al., 2000, Oncogene 19,
2286-2295; Millan and Alonso, 1998, Eur. J. Immunol.
28, 3675-3684). Briefly, IL-4-stimulated or -deprived cells
were washed in PBS and then resuspended for 2 min in
extraction buffer STE (10 mM Hepes pH 7.4, 1 mM EDTA,
0.25 mM sucrose, 2 Pg/ml aprotinin, 10 Pg/ml leupeptin,
1 mM PMSF, 1 Pg/ml pepstatin). The extract was inspect-
ed under the microscope and more than 95% of the cells
were lysed. The homogenates were applied to a linear
gradient sucrose (0.73 to 1.9M) and ultracentrifuged at
20,000 g overnight. The banded organelles were recov-
ered by syringe, diluted with an equal volume of 10 mM
Hepes buffer and sedimented at the speed appropriated
for the respective organelles. The purity of the organelles
was determined by Western blot using antibodies against
specific markers: anti-cytochrome C for mitochondria,
anti- Lck and CTx- Biotin for rafts, anti-calnexin for endo-
plasmic reticulum (ER) and anti- caspase 3 for cytosol.
For preparation of cytosol, the homogenate was precen-
trifuged at 750 g for 10 min to remove nuclei and unbroken
cells, followed by a centrifugation a 100,000 g for 1 h to
clear off the membranes.
1.5 CTx- FITC labeling
[0093] IL-4- stimulated or -deprived cells were fixed
with 1% paraformaldehyde for 5 min on ice, permeabi-
lized and then incubated with CTx-FITC (20 min, 6 Pg/ml)
and anti-Bad antibody for 1 h in PBS- BSA. Cy3-labeled
secondary antibody was added and incubated for 1 h.
Finally, and after several washing steps, cells were incu-
bated with methanol at -20°C for 10 min, mounted wiht
Vectashield medium, and analyzed by confocal micros-
copy. The program used for quantification of samples
was Leica TSC NT version 1.5.451 (Leica, Lasertechnik,
Heidelberg, Germany).
1.6 Cholesterol depletion
[0094] IL-4- stimulated serum-deprived cells were
treated for 30 min at 37°C with 10 mM M-β-CD, washed
and then incubated with CTx-FITC and anti- Bad or anti-
Lck antibodies as above. Secondary antibody was added
and incubated for 1 h. Finally, cells were incubated with
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methanol at -20°C for 10 min and mounted as described
above.
1.7 Triton X- 100 flotation
[0095] IL-4-stimulated or -deprived cells were lysed in
TXNE buffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 5
mM EDTA, 0.2% Triton X-100) containing protease in-
hibitor mixture. Detergent insoluble membranes were
isolated by ultracentrifugation (17,000 g, 4h, 4°C) in
30-35% gradient of Optiprep as previously described
(Mañes et al., 1999, EMBO J. 18, 6211-6220).
1.8 Isolation of mitochondria and S-100 fraction
[0096] Mitochondria were isolated using a modification
of the method described by Yang et al., 1997, Science
275: 1129. Briefly, 20  106 cells were IL- 4 stimulated
or deprived, harvested, and washed with ice-cold PBS.
Cell pellet was suspended in 5 vol. ice-cold buffer A (20
Mm HEPES-KOH (pH 7.5), 10mM KCl, 1,5 mM MgCl2,
1mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF,
and 250 mM sucrose) supplemented with protease in-
hibitors. Cells were disrupted in a Dounce homogenizer
(Kontes, Vineland, NJ), the nucleic were centrifuged
(1.000  g, 10 min. 4°C), and the supernatant was further
centrifuged (1.000  g. 15 min., 4°C). The resulting mi-
tochondrial pellet was resuspended in buffer A and stored
at -80°C. The supernatant was centrifuged (100,000 
g, 1 h, 4°C), and the resulting S- 100 fraction was stored
at -80°C.
2. RESULTS
2.1 Bad associates with lipid rafts in IL-4-stimulated 
cells
[0097] It has been shown that after IL-3- stimulation,
Bad becomes phosphorylated, resulting in association
to 14-3-3 protein. More recently, it has been shown that
IL-2 induces Bad phosphorylation, but not association
with 14-3-3 protein (Ayllón et al., 2001, J. Immunol. 166,
7345-7352). Figure 1 shows that neither IL- 4- stimulation
nor IL- 4-deprivation results in association of Bad to
14-3-3 protein. As internal control, the interaction of Raf
and the 14-3-3 protein is shown (Fig 1).
[0098] The subcellular distribution of Bad in IL-4-stim-
ulated or -deprived cells has been analyzed. IL-4-stimu-
lated or -deprived cells were lysed and fractionated over
sucrose gradient. To validate the gradient protocol, frac-
tions (1 to 4) were immunoblotted with markers for rafts
(Lck and GM1 ganglioside), mitochondria (cytochrome
C), endoplasmic reticulum (calnexin) and cytosol (cas-
pase 3). Nuclear fraction (fraction 5) is not shown in the
blot because there is not Bad localization in the nucleus.
Rafts were detected by western blot in fraction 1 using
anti- Lck antibody and CTx- Biotin, which recognizes GM1
ganglioside (Fig 2A). Most of Bad was found in rafts (frac-
tion 1), although a very small fraction was also present
in mitochondria (fraction 4), cytosol and endoplasmic re-
ticulum (fraction 2). As internal control, Bad was ob-
served in total extracts of IL-4-stimulated cells. Finally, it
has been observed that the fraction of Bad that is se-
questered in lipid rafts is dephosphorylated.
[0099] It has been previously reported that Bcl- 2 is ex-
pressed in IL- 2- stimulated cells and Bcl- XL in IL-4 cul-
tured cells (Gomez, J. et al, 1998, Oncogene 17: 1235).
When IL-4- maintained cells are deprived of lymphokine,
they undergo apoptosis. As early as 4 h after IL-4 depri-
vation, ≈ 9% of the cells were apoptotic, reaching 40%
at 24h, whereas control IL-4-stimulated cells showed no
significant level of apoptosis.
[0100] IL-4-deprivation induces disorganization of
rafts (fraction 1), which are not detected using either anti-
Lck antibody or CTx-Biotin. The mitochondria marker,
which also contains other cellular structures with similar
density, is observed in fraction 4 and most of the caspase
3 is cleaved, given a new protein of lower molecular
weight. More interesting, Bad is almost undetectable in
cytosol and rafts are only observed in fraction 4, which
corresponds to mitochondria and cellular structures with
similar density (Fig 2A). This result strongly suggests an
IL-4-dependent association of Bad with rafts and trans-
location to mitochondria upon IL-4-deprivation. Rafts
were also isolated by Triton X-100 flotation gradient. As
shown in Fig 2B, Bad and Lck are detected in the deter-
gent insoluble fraction (I) of IL- 4-stimulated cells, which
corresponds to lipid rafts. In IL-4-deprived cells, Bad and
Lck are detected in the fraction corresponding to soluble
proteins (S). It has been observed that post- translational
myristoylation targets Bad to rafts (data not shown).
[0101] The subcellular localization of Bad was also an-
alyzed in mitochondrial and cytosolic fractions of IL-4-
stimulated or -deprived cells. Bad was detected in the
mitochondrial fraction of IL- 4-stimulated cells. The
amount of Bad associated with mitochondria increased
upon IL- 4 deprivation. Traces of Bad were detected in
the cytosolic fraction of IL-4 stimulated or -deprived cells.
The antiapoptotic molecule Bcl-xL was weakly detected
in the mitochondrial fraction of IL- 4-stimulated cells, in-
creasing after IL-4 deprivation. As an internal control of
protein fractionation, the blot was probed with anti- cas-
pase 3 (cytosolic marker), anti- mitochondria Mito 2813
(pyruvate dehydrogenase, mitochondrial marker), and
anti- calnexin to show the lack of endoplasmic reticulum
contamination in mitochondrial preparation. Total ex-
tracts (late T) were used as a positive control of calnexin
expression. Finally, the association of Bad with some Bcl-
2 family members was explored. Coimmunoprecipitation
experiments of cytoplasmic proteins under IL-4 stimula-
tion or deprivation conditions using specific antibodies
were performed. Bad was detected by Western blot in
anti- Bcl- XL immunoprecipitates of IL-4 stimulated cells,
decreasing throughout the starvation period analyzed.
Probing the membrane with anti-Bcl-XL antibodies
showed similar levels in all analyzed conditions.
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[0102] Bad association to rafts in IL-4-stimulated cells
was also analyzed in intact cells by confocal microscopy
(Fig 3A). IL- 4-stimulated or -deprived cells were incubat-
ed with the raft marker cholera toxin B subunit (CTx-FITC)
before secondary labelling with anti-Bad or anti-Lck an-
tibody. Double immunofluorescence analysis with anti-
Bad and CTx-FITC showed raft localization of Bad in the
surface of IL-4- stimulated cells. In marked contrast, a
disorganization of rafts in IL-4- deprived cells was ob-
served and consequently, no rafts localization of Bad in
IL-4- deprived cells (Fig 3A). Double immunofluores-
cence analysis with anti-Lck and CTx-FITC was used as
a positive control of localization of Lck in membrane rafts
of IL-4-stimulated cells. Lck associated with rafts was not
detected in IL- 4-deprived cells (Fig 3A).
[0103] The profile of green and red fluorescence colo-
calization was analyzed using the quantification software
of Leica (TCS NT; Leica, Rockleigh, NJ). A high number
of green and red colocalization peaks was observed in
the membrane of IL-4 stimulated cells stained with CTx-
Lck or CTx-Bad. On the contrary, the level of colocaliza-
tion of green and red fluorescence was strongly reduced
in IL-4-deprived cells.
[0104] This result suggests that Bad is preferentially
localized in lipid rafts in IL- 4- stimulated cells and segre-
gates from plasma membrane in IL-4-deprived cells.
[0105] Similar results of colocalization of Bad with lipid
rafts were observed using freshly isolated thymocytes
from mice.
[0106] Bad association with mitochondria in IL-4-de-
prived cells was also analyzed in intact cells by confocal
microscopy (Fig 3B). Double immunofluorescence anal-
ysis with anti- Bad and anti-mitochondria antibodies
shows weak association of Bad to mitochondria in IL-4-
stimulated cells while there is a high fraction of Bad as-
sociated to mitochondria in IL-4-deprived cells (Fig 3B).
This separation of Bad from rafts correlates with its trans-
location to mitochondria in IL-4- deprived cells, as shown
by cellular fractionation and confocal microscopy (Fig 2A
and 2B).
[0107] The profile of green and red fluorescence colo-
calization was also analyzed using quantification soft-
ware (Leica) and showed moderate green and red colo-
calization peaks in IL-4-stimulated cells stained with anti-
Bad and anti-mitochondria Abs. The level of colocaliza-
tion of both fluorescences strongly increased in IL-4 de-
prived cells.
2.2 Association of Bad to lipid rafts is required for 
prevention of apoptosis
[0108] Depletion of cellular cholesterol impairs the
ability of glycosyl phosphatidylinositol (GPI)-anchored
proteins to associate with lipid rafts. To examine whether
there is a similar requirement of cholesterol for the asso-
ciation of Bad with rafts, IL-4-stimulated cells were treat-
ed for 30 min with or without 10 mM methyl-β-cyclodextrin
(M-β-CD) in serum- free medium to deplete cellular cho-
lesterol. Cells were then incubated with CTx-FITC and
labeled with anti-Bad or anti-Lck antibodies. Serum de-
pletion alone weakly disrupt the association of Lck or Bad
to lipid rafts (Fig 4A). However, M-β-CD treatment causes
a severe disruption of raft formation and association of
Lck and Bad with rafts in IL-4-stimulated cells (Fig 4A).
This result indicates that disruption of raft formation by
cholesterol depletion induces segregation of Bad and Lck
from rafts in IL- 4-stimulated cells.
[0109] Given that exclusion of Bad from rafts was also
observed in apoptotic IL-4-deprived cells (Fig 3A), it was
analyzed whether Bad association to rafts and its integrity
was necessary for prevention of apoptosis. For this pur-
pose, IL-4-stimulated cells were treated for 30 min with
or without M-β-CD in serum- free medium, then washed,
resuspended in IL-4-supplemented complete medium
and analyzed for induction of apoptosis at different times
(Fig 4B). M-β-CD treated cells showed stronger level of
apoptosis compared with control non treated cells, reach-
ing the highest level 5 hours after M- β-CD treatment.
Eight hours upon treatment, the amount of apoptotic cells
detected in treated and non treated cells were similar
because addition of serum restores the lipid composition
of the membrane.
[0110] This result suggests that segregation of Bad
from rafts is involved in the induction of apoptosis. Post-
translational modifications of Bad such as phosphoryla-
tion, and its role in Bad localization in rafts or mitochon-
dria was further analyzed. Figure 5A shows that IL-4 in-
duces serine 136 phosphorylation of Bad, but not serine
112 and 155. Moreover, IL- 4-deprivation induces serine
136 dephosphorylation of Bad. Given that IL-4 induces
serine 136 phosphorylation of Bad, western blot was rep-
robed from Figure 2A with anti-Bad serine 136 antibody.
Figure 5B shows that while most of Bad is localized in
rafts in IL-4-stimulated cells, only the weak cytosolic frac-
tion of Bad is serine 136 phosphorylated. In IL-4-deprived
cells, traces of serine 136 phosphorylation are observed
in cytosol and mitochondria. This result suggests that
dephosphorylated Bad is sequestered in rafts and IL- 4-
deprivation induces segregation and translocation to mi-
tochondria.
[0111] Subcellular localization of Bad enables to dis-
cover how Bad function may be regulated by dynamic
interaction with lipid rafts or mitochondria. The distinct
Bad distribution and function is directly related to IL-4-
stimulation or -deprivation of the cells.
[0112] These data show that 14-3-3 protein does not
control the proapoptotic role of Bad, contrary to previous
reports. On the basis of this result, the subcellular distri-
bution of Bad in IL-4-stimulated or -deprived cells was
analyzed. These results show that different plasma mem-
brane fractions can be separated using subcellular frac-
tionation sucrose ultracentrifugation gradient because
raft markers were successfully resolved from non- rafts
markers. Rafts and mitochondria were also isolated by
Triton X-100 flotation gradient and differential centrifu-
gations, respectively. There are precedents for reversible
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raft association as has been shown following the move-
ment of single fluorescence lipid molecules (Schutz et
al., 2000, EMBO J. 19, 892-901). In addition, after acti-
vation by ligand binding , the epidermal growth factor mi-
grates out of rafts into bulk plasma membrane (Mineo et
al., 1999, J. Biol. Chem. 274, 30636-30643). The asso-
ciation of proteins with lipid rafts can be modulated be-
cause some proteins may be excluded from rafts by as-
sociation to other proteins (Field et al., 1995, Proc. Natl.
Acad. Sci. USA. 92, 9201-9205). Association of Bad with
rafts may be involved in steps leading to Bad inactivation,
because rafts do not constitute the final site of activation.
IL-4-deprivation induces segregation of Bad from rafts.
This results suggests a two steps apoptotic process: first,
segregation of Bad from rafts, that triggers apoptosis and
second, disorganization of lipid rafts during apoptotic
process. This is strongly suggested by results showing
that disruption of cholesterol rich rafts prevents Bad as-
sociation and induces apoptosis in IL- 4- stimulated M- β-
CD-treated cells. Addition of fetal calf serum to IL-4- sup-
plemented medium restores the lipid components of the
plasma membrane, preventing progression of apoptosis.
[0113] Localization of proteins to distinct subcellular
fractions is an essential step in multiple signaling path-
ways, including apoptosis. According to this, it has been
shown that some signaling molecules are sequestered
in rafts. Cholesterol depletion disrupts lipid rafts and mod-
ulates the activity of multiple signaling pathways in T lym-
phocytes (Kabouridis et al., 2000, Eur. J. Immunol. 30,
954-963). These results strongly suggest that in the ab-
sence of association of Bad to 14-3-3 protein, Bad is se-
questered in rafts, avoiding a proapoptotic role and as-
sociation with partners. IL-4 deprivation-induced segre-
gation of Bad from rafts correlates with translocation to
mitochondria and induction of apoptosis. Restriction of
intermolecular interactions by sequestration in lipid rafts
has been also described fro the α-chain of the IL-2R,
avoiding its association with the β-and γ-chains of the IL-
2R (Marmor, M; and M. Julius, 2001, Blood 98:1489). It
is interesting to notice that in IL-4-stimulated cells, most
of cellular Bad localizes in rafts in a dephosphorylated
condition while the weak cytosolic fraction is serine 136
phosphorylated. These results show for the first time the
sequestration of a pro-apoptotic protein into lipid rafts as
a mechanism that controls the availability of said proap-
optotic protein.
Claims
1. A method of screening cellular polypeptides for pro-
apoptotic or anti-apoptotic activity in a cell of a par-
ticular cell- type, said method comprising
a. culturing cells of said particular cell-type under
non apoptotic conditions and culturing cells of
said particular cell- type under apoptotic condi-
tions; and,
b. determining subcellular localisation of said
cellular polypeptides in the cultured cells;
wherein a localization of a cellular polypeptide in lipid
rafts in cultured cells under non apoptotic conditions
and a segregation of said cellular polypeptide from
lipid rafts in cultured cells under apoptotic conditions
is indicative that said cellular polypeptide has a pro-
apoptotic or an anti-apoptotic activity in said partic-
ular cell-type.
2. The method of Claim 1, wherein said screened cel-
lular polypeptides belong to the Bcl-2 family and their
subcellular localisation is determined by the use of
a molecule which specifically recognizes a BH do-
main.
3. The method of Claim 2, wherein said screened cel-
lular polypeptides are isolated from biochemically
isolated lipid rafts of said cells cultured in non apop-
totic conditions by the use of a molecule which spe-
cifically recognizes a BH domain.
4. The method of any of Claims 2 to 3, wherein said
screened cellular polypeptides are further isolated
by the use of a molecule which specifically recogniz-
es a mirystoylated polypeptide.
5. The method according to any of Claims 1 to 4, where-
in said cell- type is characterized by the production
of Bad protein (Bad+ cell type), preferably is com-
posed of cells of the immune system, and most pref-
erably of T cell lines.
6. The method according to Claim 5, wherein said
screened cellular polypeptides are isolated from bi-
ochemically isolated lipid rafts of said cells cultured
under non apoptotic conditions and selected among
the cellular polypeptides which physically interact
with the Bad protein.
7. The method according to any of Claims 2 to 6, where-
in said BH domain is the BH4 domain.
8. The method according to any of Claims 2 to 6, where-
in said BH domain is the BH3 domain.
9. A method of screening compounds for their capacity
to modulate apoptosis in cells which produce pro- or
anti- apoptotic polypeptides which are located in lipid
rafts when said cells are cultured under non apop-
totic conditions, said method comprising: 
a. culturing said cells in a growth medium for
maintaining non apoptotic conditions;
b. contacting said cultured cells with a candidate
compound;
c. determining the level of one or several pro- or
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anti- apoptotic polypeptides associated to lipid
rafts ; and,
d. selecting the compound which interferes with
the association of one or several pro- or anti-
apoptotic polypeptides with lipid rafts, said com-
pound having the capacity to modulate apopto-
sis.
10. A method of screening compounds for their capacity
to promote apoptosis in cells, said method compris-
ing
a. culturing mammalian cells in a growth medium
for maintaining non apoptotic conditions; where-
in said cells produce a pro- apoptotic protein
which is located in lipid rafts under non apoptotic
conditions of said cells;
b. contacting said cultured cells with a candidate
compound; and,
c. determining the absence or the presence of
lipid rafts in said cultured cells;
d. in case of presence of lipid rafts, optionally
determining the level of pro-apoptotic protein lo-
cated in the lipid rafts,
wherein the absence of lipid rafts in the plasma mem-
brane of cells incubated with said candidate com-
pound or if determined, the reduced level of pro-ap-
optotic protein in the rafts is indicative that said com-
pound promotes apoptosis.
11. A method of screening compounds for their capacity
to inhibit or prevent apoptosis of cells, said method
comprising
a. culturing cells in a growth medium for main-
taining non apoptotic conditions; wherein said
cells produce a pro-apoptotic protein which is
located in lipid rafts under non apoptotic condi-
tions;
b. contacting said cells with a candidate com-
pound;
c. culturing cells under apoptotic conditions;
d. determining the absence or the presence of
lipid rafts;
e. in the case of presence of lipid rafts, optionally
determining the level of pro-apoptotic protein lo-
cated in the lipid rafts;
wherein the presence of lipid rafts in the plasma
membranes of cells incubated with said candidate
compound and optionally the maintained level of pro-
apoptotic protein in the rafts is indicative that said
candidate compound inhibits or prevents apoptosis.
12. The method according to Claim 9, 10 or 11, wherein
a pro-apoptotic protein located in lipid rafts under
proliferative conditions is the Bad protein.
13. The method of Claim 12, wherein said cells which
produce a Bad protein are cells characteristic of the
immune system, preferably T cells.
14. The method according to any of Claims 9 to 13,
wherein the presence or the absence of lipid rafts is
visualized by confocal microscopy.
15. The method according to any of Claims 9 to 13,
wherein the presence or the absence of lipid rafts is
determined by the following steps
i) recovering the cultured cells incubated with
said compound candidate and resuspending
said cells in a buffer appropriate for subcellular
fractionation, such as gradient sucrose buffer;
ii) ultracentrifugating the fractionated cells and;
iii) recovering the subcellular fraction which
should contain lipid rafts;
iv) determining whether the recovered subcel-
lular fraction contains ganglioside and/or lipid
raft associated molecule(s).
16. The method according to Claim 14 or 15, wherein
the presence or the absence of lipid rafts is deter-
mined by the use of a marker which specifically rec-
ognizes ganglioside or a raft- associated molecule.
17. The method according to Claim 16, wherein said
marker is selected among cholera toxin subunit B
(CTx), anti-Bad antibody or anti- Lck antibody.
18. The method of anyone of claims 1 to 18, wherein
said cells are mammalian cells.
19. The method of anyone of claims 1 to 19, wherein
said non apoptotic conditions are proliferative con-
ditions.
20. The method of anyone of claims 9 to 13 or 15 to 18
and 19, wherein said growth medium comprises at
least a cytokine or a growth factor necessary for
maintaining proliferative growth conditions.
21. The method of anyone of claims 11, 17 or 20, wherein
the apoptotic conditions of step c) are obtained by
depriving the cells with said cytokine or growth factor.
22. The method of claim 20, wherein a cytokine or growth
factor necessary for maintaining proliferative growth
conditions is an interleukin, preferably selected
among IL-4, IL- 2 or IL-9, or a mixture thereof.
23. A use of a compound capable of reconstituting lipid
rafts in the preparation of a medicine for the treat-
ment of disorders induced by or associated with a
defective regulation of cell death resulting in an ab-
normal increase of cell death or of any specific pa-
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thology in which cell death may be at least a part of
the therapy.
24. The use of Claim 23, wherein said defective regula-
tion affects cells which produce Bad protein.
25. The use of Claim 24, wherein said defective regula-
tion affects cells of the immune system.
26. The use of Claim 23. wherein a pathology resulting
in an abnormal increase of cell death is a disease
associated to senescence, neuro- degenerative dis-
ease Alzheimer, AIDS, ischemic cell death or wound-
healing.
27. The use of any of Claims 23 and 26, wherein a com-
pound capable of reconstituting lipid rafts is edelfo-
sine.
28. An in vitro method for the detection of a defective
regulation of apoptosis, in a sample of cells of an
individual, said method comprising determining the
presence or the absence of lipid rafts in said cells,
wherein the absence of said lipid rafts is indicative
of a defective regulation of apoptosis.
29. The method according to Claim 28, wherein said
cells are cells of the immune system of an individual
affected by a lymphoproliferative disease.
30. The method of any of Claims 28 to 29, wherein the
presence or the absence of lipid rafts is determined
by detecting the presence or absence of a pro-ap-
optotic or an anti- apoptotic protein which is known
to be located in lipid rafts under non apoptotic con-
ditions of cells.
31. The method of Claim 30, wherein a pro-apoptotic
protein known to be located in lipid rafts under non
apoptotic conditions is a Bad protein.
32. A use of a compound appropriate for detecting the
presence of lipid rafts, in the in vitro detection method
according to any of Claims 28 to 31.
33. The use of Claim 32, wherein a compound appropri-
ate for detecting the presence of lipid rafts is a com-
pound which specifically recognizes Bad protein, Lck
protein or ganglioside GM1.
34. The use of Claim 33, wherein said compound is se-
lected among cholera toxin subunit B (CTx), anti-
Bad antibody and anti-Lck antibody.
35. A use of a compound capable of modulating a protein
of Bcl- 2 family rafts localization for the preparation
of a medicine for the treatment of disorders induced
by or associated with a defective regulation of cell
death or of any specific pathology in which cell death
may be at least a part of the therapy.
36. The use of claim 35, wherein said compound pro-
mote a protein of Bcl- 2 family segregation from lipid
rafts.
37. The use of claim 35, wherein said compound pro-
motes a protein of Bcl-2 family localization in lipid
rafts.
38. An in vitro method for the detection of a defective
regulation of apoptosis, in a sample of cells of an
individual, said method comprising determining the
presence or the absence of lipid rafts in said cells,
wherein the presence of a great number of lipid rafts
compared to normal cells is indicative of a defect
regulation of apoptosis.
Patentansprüche
1. Verfahren, zum Screenen zellulärer Polypeptide hin-
sichtlich pro-apoptotischer oder antiapoptotischer
Aktivität in einer Zelle von einem bestimmten Zelltyp,
wobei das Verfahren folgendes umfasst
a. Kultivieren von Zellen des bestimmten Zell-
typs unter nicht-apoptotischen Bedingungen,
und Kultivieren von Zellen des bestimmten Zell-
typs unter apoptotischen Bedingungen; und
b. Bestimmen der subzellulären Lokalisation der
zellulären Polypeptide in den kultivierten Zellen;
wobei eine Lokalisierung eines zellulären Polypep-
tids in Lipidflößen in kultivierten Zellen unter nicht-
apoptotischen Bedingungen und eine Segregation
des zellulären Polypeptids aus Lipidflößen in kulti-
vierten Zellen unter apoptotischen Bedingungen
darauf hinweist, dass das zelluläre Polypeptid eine
pro-apoptotische oder eine anti- apoptotische Aktivi-
tät in dem bestimmten Zelltyp aufweist.
2. Verfahren von Anspruch 1, wobei die gescreenten
zellulären Polypeptide der Bcl-2-Familie angehören
und ihre subzelluläre Lokalisierung durch die Ver-
wendung eines Moleküls bestimmt wird, das spezi-
fisch eine BH-Domäne erkennt.
3. Verfahren von Anspruch 2, wobei die gescreenten
zellulären Polypeptide aus biochemisch isolierten Li-
pidflößen der bei nicht-apoptotischen Bedingungen
kultivierten Zellen durch Verwenden eines Moleküls
isoliert werden, das spezifisch eine BH-Domäne er-
kennt.
4. Verfahren von mindestens einem der Ansprüche 2
bis 3, wobei die gescreenten zellulären Polypeptide
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ferner durch die Verwendung eines Moleküls isoliert
werden, das spezifisch ein myristoyliertes Polypep-
tid erkennt.
5. Verfahren nach mindestens einem der Ansprüche 1
bis 4, wobei der Zelltyp durch die Herstellung von
Bad-Protein gekennzeichnet ist (Bad+-Zelltyp),
vorzugsweise aus Zellen des Immunsystems und
am stärksten bevorzugt aus T-Zelllinien besteht.
6. Verfahren nach Anspruch 5, wobei die gescreenten
zellulären Polypeptide aus biochemisch isolierten Li-
pidflößen der unter nicht-apoptotischen Bedingun-
gen kultivierten Zellen isoliert und aus den zellulären
Polypeptiden selektiert werden, welche mit dem
Bad-Protein physikalisch wechselwirken.
7. Verfahren nach mindestens einem der Ansprüche 2
bis 6, wobei die BH-Domäne die BH4-Domäne ist.
8. Verfahren nach mindestens einem der Ansprüche 2
bis 6, wobei die BH-Domäne die BH3-Domäne ist.
9. Verfahren zum Screenen von Verbindungen hin-
sichtlich ihres Vermögens, Apoptose in Zellen zu
modulieren, welche pro- oder anti- apoptotische Po-
lypeptide herstellen, welche in Lipidtlößen lokalisiert
sind, wenn die Zellen unter nicht-apoptotischen Be-
dingungen kultiviert werden, wobei das Verfahren
folgendes umfasst: 
a. Kultivieren der Zellen in einem Wachstums-
medium zum Aufrechterhalten von nicht- apop-
totischen Bedingungen;
b. Kontaktieren der kultivierten Zellen mit einer
Kandidatenverbindung;
c. Bestimmen des Spiegels an einem oder meh-
reren pro- oder anti- apoptotischen Polypepti-
den, welche mit Lipidflößen assoziiert sind; und
d. Auswählen der Verbindung, welche in die As-
soziation von einem oder mehreren pro-oder an-
ti-apoptotischen Polypeptiden mit Lipidflößen
eingreift, wobei die Verbindung die Fähigkeit
aufweist, Apoptose zu modulieren.
10. Verfahren zum Screenen von Verbindungen hin-
sichtlich ihres Vermögens, Apoptose in Zellen zu for-
dern, wobei das Verfahren folgendes umfasst: 
a. Kultivieren von Säugerzellen in einem
Wachstumsmedium zum Aufrechterhalten von
nicht-apoptotischen Bedingungen, wobei die
Zellen ein pro-apoptotisches Protein herstellen,
welches unter nicht-apoptotischen Bedingun-
gen der Zellen in Lipidflößen lokalisiert ist;
b. Kontaktieren der kultivierten Zellen mit einer
Kandidatenverbindung; und
c. Bestimmen der Abwesenheit oder Gegenwart
von Lipidflößen in den kultivierten Zellen;
d. im Falle der Gegenwart von Lipidflößen ge-
gebenenfalls Bestimmen des Spiegels an pro-
apoptotischem Protein, das in den Lipidflößen
lokalisiert ist,
wobei die Abwesenheit von Lipidflößen in der Plas-
mamembran von Zellen, welche mit der Kandidaten-
verbindung inkubiert wurden, oder - sofern bestimmt
- der verringerte Spiegel an pro-apoptotischem Pro-
tein in den Flößen darauf hinweist, dass die Verbin-
dung Apoptose fördert.
11. Verfahren zum Screenen von Verbindungen hin-
sichtlich ihres Vermögens, Apoptose von Zellen zu
inhibieren oder zu verhindern, wobei das Verfahren
folgendes umfasst: 
a. Kultivieren von Zellen in einem Wachstums-
medium zum Aufrechterhalten von nicht- apop-
totischen Bedingungen, wobei die Zellen ein
pro-apoptotisches Protein, welches unter nicht-
apoptotischen Bedingungen in Lipidflößen loka-
lisiert ist, herstellen;
b. Kontaktieren der Zellen mit einer Kandidaten-
verbindung;
c. Kultivieren von Zellen unter apoptotischen
Bedingungen;
d. Bestimmen der Abwesenheit oder der Gegen-
wart von Lipidflößen;
e. im Falle der Gegenwart von Lipidflößen ge-
gebenenfalls Bestimmen, des Spiegels an pro-
apoptotischem Protein, das in den Lipidflößen
lokalisiert ist;
wobei die Gegenwart von Lipidflößen in den Plas-
mamembranen von Zellen, welche mit der Kandida-
tenverbindung inkubiert wurden, und gegebenen-
falls der aufrechterhaltene Spiegel an pro- apoptoti-
schem Protein in den Flößen darauf hinweist, dass
die Kanndidatcnverbindung Apoptose inhibiert oder
verhindert.
12. Verfahren gemäß Anspruch 9, 10 oder 11, wobei ein
pro-apoptotisches Protein, das unter proliferativen
Bedingungen in Lipidflößen lokalisiert ist, das Bad-
Protein ist.
13. Verfahren von Anspruch 12, wobei die Zellen, die
ein Bad-Protein herstellen, für das Immunsystem
charakteristische Zellen, vorzugsweise T-Zellen,
sind.
14. Verfahren nach mindestens einem der Ansprüche 9
bis 13, wobei die Gegenwart oder Abwesenheit von
Lipidflößen durch konfokale Mikroskopie sichtbar
gemacht wird.
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15. Verfahren nach mindestens einem der Ansprüche 9
bis 13, wobei die Gegenwart oder Abwesenheit von
Lipidflößen durch die folgenden Schritte bestimmt
wird: 
i) Gewinnen der kultivierten, mit dem Verbin-
dungs-Kandidaten inkubierten Zellen und Re-
suspendieren der Zellen in einem Puffer, der für
subzelluläre Fraktionierung geeignet ist, wie ei-
nem Gradienten-Saccharose-Puffer;
ii) Ultrazenlrifugieren der fraktionierten Zellen,
und;
iü) Rückgewinnen der subzellulären Fraktion,
welche Lipidflöße enthalten sollte;
iv) Bestimmen, ob die rückgewonnene subzel-
luläre Fraktion Gangliosid und/ oder Lipidfloß-
assoziierte Molekül(e) enthält.
16. Verfahren gemäß Anspruch 14 oder 15, wobei die
Gegenwart oder Abwesenheit von Lipidflößen durch
die Verwendung eines Markers bestimmt wird, der
spezifisch Gangliosid oder ein Floß-assoziiertes Mo-
lekül erkennt.
17. Verfahren gemäß Anspruch 16, wobei der Marker
unter Choleratoxin-Untereinheit B (CTx), Anti-Bad-
Antikörper oder Anti-Lck-Antikörper gewählt wird.
18. Verfahren von mindestens einem der Ansprüche 1
bis 18, wobei die Zellen Säugerzellen sind.
19. Verfahren von mindestens einem der Ansprüche 1
bis 19, wobei die nicht-apoptotischen Bedingungen
proliferative Bedingungen sind.
20. Verfahren von mindestens einem der Ansprüche 9
bis 13 oder 15 bis 18 und 19, wobei das Wachstums-
medium mindestens ein Cytokin oder einen Wachs-
tumsfaktor umfasst, welches(r) notwendig zum Auf-
rechterhalten von proliferativen Wachstumsbedin-
gungen ist.
21. Verfahren von mindestens einem der Ansprüche 11,
17 oder 20, wobei die apoptotischcn Bedingungen
von Schritt c) erhalten werden, indem man den Zel-
len das Cytokin oder den Wachstumsfaktor entzieht.
22. Verfahren von Anspruch 20, wobei ein Cytokin oder
Wachstumsfaktor, welches (r) notwendig zum Auf-
rechterhalten von proliferativen Wachstumsbedin-
gungen ist, ein Interleukin, vorzugsweise gewählt
aus IL- 4, IL-2 oder IL-9, oder eine Mischung von die-
sen ist.
23. Verwendung einer Verbindung, die zum Rekonstitu-
ieren von Lipidflößen in der Lage ist, in der Herstel-
lung eines Medikamentes für die Behandlung von
Störungen, welche induziert werden durch oder as-
soziiert sind mit einer fehlerhaften Regulierung des
Zelltodes, welche zu einer abnormen Erhöhung des
Zelltodes führt, oder jeglicher spezifischen Patholo-
gie, in welcher Zelltod wenigstens ein Teil der The-
rapie sein kann.
24. Verwendung von Anspruch 23, wobei die fehlerhafte
Regulierung Zellen betrifft, welche Bad-Protein pro-
duzieren.
25. Verwendung von Anspruch 24, wobei die fehlerhafte
Regulierung Zellen des Immunsystems betrifft.
26. Verwendung von Anspruch 23, wobei eine Patholo-
gie, welche zu einer abnormen Erhöhung des Zell-
todes führt, eine mit Senszenz assoziierte Krankheit,
die neurodegenerative Alzheimer-Krankheit, AIDS,
ischämischer Zelltod oder Wundheilung ist.
27. Verwendung von mindestens einem der Ansprüche
23 und 26, wobei eine Verbindung, die zum Rekon-
stituieren von Lipidflößen in der Lage ist, Edelfosin
ist.
28. In- vitro- Verfahren zum Detektieren einer fehlerhaf-
ten Regulierung von Apoptose in einer Probe von
Zellen eines Individuums, wobei das Verfahren das
Bestimmen der Gegenwart oder Abwesenheit von
Lipidflößen in den Zellen umfasst, wobei die Abwe-
senheit der Lipidflöße kennzeichnend für eine feh-
lerhafte Regulierung von Apoptose ist.
29. Verfahren gemäß Anspruch 28, wobei es sich bei
den Zellen um Zellen des Immunsystems eines In-
dividuums handelt, das von einer lymphoproliferati-
ven Krankheit betroffen ist.
30. Verfahren von mindestens einem der Ansprüche 28
bis 29, wobei die Gegenwart oder Abwesenheit von
Lipidflößen durch Detektieren der Gegenwart oder
Abwesenheit eines pro-apoptotischen oder eines
anti-apoptotischen Proteins bestimmt wird, von dem
bekannt ist, dass es unter nicht-apoptotischen Be-
dingungen von Zellen in Lipidflößen lokalisiert ist.
31. Verfahren von Anspruch 30, wobei ein pro-apopto-
tisches Protein, von dem bekannt ist, dass es unter
nicht- apoptotischen Bedingungen in Lipidflößen lo-
kalisiert ist, ein Bad-Protein ist.
32. Verwendung einer Verbindung, die zum Detektieren
der Gegenwart von Lipidflößen geeignet ist, in dem
in vitro-Detektionsverfahren gemäß mindestens ei-
nem der Ansprüche 28 bis 31.
33. Verwendung von Anspruch 32, wobei eine Verbin-
dung, die zum Detektieren der Gegenwart von Lipid-
flößen geeignet ist, eine Verbindung ist, welche spe-
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zifisch Bad-Protein, Lck- Protein oder Gangliosid
GM1 erkennt.
34. Verwendung von Anspruch 33, wobei die Verbin-
dung unter Choleratoxin-Untereinheit B (CTx), Anti-
Bad-Antikörper und Anti-Lck- Antikörper gewählt
wird.
35. Verwendung einer Verbindung, die zum Modulieren
der Lokalisierung eines Proteins der Bcl- 2-Familie
in Flößen in der Lage ist, zur Herstellung eines Me-
dikamentes für die Behandlung von Störungen, die
induziert werden durch oder assoziiert sind mit einer
fehlerhaften Regulierung des Zelltodes, oder jegli-
cher spezifischen Pathologie, in welcher Zelltod we-
nigstens ein Teil der Therapie sein kann.
36. Verwendung von Anspruch 35, wobei die Verbin-
dung die Segregation eines Proteins der Bcl- 2-Fa-
milie aus Lipidflößen fördert.
37. Verwendung von Anspruch 35, wobei die Verbin-
dung die Lokalisierung eines Proteins der Bcl-2-Fa-
milie in Lipidflößen fördert.
38. In- vitro-Verfahren zum Detektieren einer fehlerhaf-
ten Regulierung von Apoptose in einer Probe von
Zellen eines Individuums, wobei das Verfahren das
Bestimmen der Gegenwart oder Abwesenheit von
Lipidflößen in den Zellen umfasst, wobei die Gegen-
wart einer großen Anzahl an Lipidflößen im Vergleich
zu normalen Zellen kennzeichnend für eine fehler-
hafte Regulierung von Apoptose ist.
Revendications
1. Procédé de criblage de polypeptides cellulaires pour
une activité pro-apoptotique ou anti-apoptotique
dans une cellule d’un type cellulaire particulier, ledit
procédé comprenant :
a. la culture de cellules dudit type cellulaire par-
ticulier dans des conditions non apoptotiques et
la culture de cellules dudit type cellulaire parti-
culier dans des conditions apoptotiques ; et
b. la détermination de la localisation sous-cellu-
laire desdits polypeptides cellulaires dans les
cellules cultivées ;
dans lequel une localisation d’un polypeptide cellu-
laire dans des radeaux lipidiques dans les cellules
cultivées dans des conditions non apoptotiques et
une ségrégation dudit polypeptide cellulaire depuis
des radeaux lipidiques dans les cellules cultivées
dans des conditions apoptotiques indiquent que ledit
polypeptide cellulaire possède une activité pro-
apoptotique ou anti-apoptotique dans ledit type cel-
lulaire particulier.
2. Procédé selon la revendication 1, dans lequel lesdits
polypeptides cellulaires criblés appartiennent à la fa-
mille Bcl-2 et leur localisation sous-cellulaire est dé-
terminée par l’utilisation d’une molécule qui recon-
naît spécifiquement un domaine BH.
3. Procédé selon la revendication 2, dans lequel lesdits
polypeptides cellulaires criblés sont isolés à partir
de radeaux lipidiques biochimiquement isolés des-
dites cellules cultivées dans des conditions non
apoptotiques par l’utilisation d’une molécule qui re-
connaît spécifiquement un domaine BH.
4. Procédé selon l’une quelconque des revendications
2 à 3, dans lequel lesdits polypeptides cellulaires
criblés sont en outre isolés par l’utilisation d’une mo-
lécule qui reconnaît spécifiquement un polypeptide
myristoylé.
5. Procédé selon l’une quelconque des revendications
1 à 4, dans lequel ledit type cellulaire est caractérisé
par la production de la protéine Bad (type cellulaire
Bad*), de préférence est composé de cellules du
système immunitaire, et le plus préférentiellement
de lignées de cellules T.
6. Procédé selon la revendication 5, dans lequel lesdits
polypeptides cellulaires criblés sont isolés à partir
de radeaux lipidiques biochimiquement isolés des-
dites cellules cultivées dans des conditions non
apoptotiques et choisis parmi les polypeptides cel-
lulaires qui, interagissent physiquement avec la pro-
téine Bad.
7. Procédé selon l’une quelconque des revendications
2 à 6, dans lequel ledit domaine BH est le domaine
BH4.
8. Procédé selon l’une quelconque des revendications
2 à 6, dans lequel ledit domaine BH est le domaine
BH3.
9. Procédé de criblage de composés pour leur capacité
à moduler l’apoptose dans des cellules qui produi-
sent des polypeptides pro- ou anti-apoptotiques qui
sont situés dans des radeaux lipidiques quand les-
dites cellules sont cultivées dans des conditions non
apoptotiques, ledit procédé comprenant :
a. la culture desdites cellules dans un milieu de
croissance pour maintenir des conditions non
apoptotiques ;
b. la mise en contact desdites cellules cultivées
avec un composé candidat ;
c. la détermination du niveau d’un ou plusieurs
polypeptides pro- ou anti-apoptotiques associés
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à des radeaux lipidiques ; et
d. la sélection du composé qui interfère avec
l’association d’un ou plusieurs polypeptides pro-
ou anti-apoptotiques avec des radeaux lipidi-
ques, ledit composé possédant la capacité de
moduler l’apoptose.
10. Procédé de criblage de composés pour leur capacité
à favoriser l’apoptose dans des cellules, ledit procé-
dé comprenant : 
a. la culture de cellules de mammifère dans un
milieu de croissance pour maintenir des condi-
tions non apoptotiques ; dans lequel lesdites
cellules produisent une protéine pro-apoptoti-
que qui est située dans des radeaux lipidiques
dans des conditions non apoptotiques de culture
desdites cellules ;
b. la mise en contact desdites cellules cultivées
avec un composé candidat ; et
c. la détermination de l’absence ou de la pré-
sence de radeaux lipidiques dans lesdites cel-
lules cultivées;
d. en cas de présence de radeaux lipidiques, la
détermination éventuelle du niveau de protéine
pro-apoptotique située dans les radeaux
lipidiques ;
dans lequel l’absence de radeaux lipidiques dans la
membrane plasmatique de cellules incubées avec
ledit composé candidat ou, s’il est déterminé, le ni-
veau réduit de protéine pro-apoptotique dans les ra-
deaux, indique que ledit composé favorise l’apopto-
se.
11. Procédé de criblage de composés pour leur capacité
à inhiber ou prévenir l’apoptose de cellules, ledit pro-
cédé comprenant :
a. la culture de cellules dans un milieu de crois-
sance pour maintenir des conditions non
apoptotiques ; dans lequel lesdites cellules pro-
duisent une protéine pro-apoptotique qui est si-
tuée dans des radeaux lipidiques dans des con-
ditions non apoptotiques ;
b. la mise en contact desdites cellules avec un
composé candidat ;
c. la culture de cellules dans des conditions
apoptotiques ;
d. la détermination de l’absence ou de la pré-
sence de radeaux lipidiques ;
e. en cas de présence de radeaux lipidiques, la
détermination éventuelle du niveau de protéine
pro- apoptotique située dans les radeaux
lipidiques ;
dans lequel la présence de radeaux lipidiques dans
les membranes plasmatiques de cellules incubées
avec ledit composé candidat et éventuellement le
niveau maintenu de protéine pro-apoptotique dans
les radeaux indiquent que ledit composé candidat
inhibe ou prévient l’apoptose.
12. Procédé selon la revendication 9, 10 ou 11, dans
lequel une protéine pro-apoptotique située dans des
radeaux lipidiques dans des conditions prolifératives
est la protéine Bad.
13. Procédé selon la revendication 12, dans lequel les-
dites cellules qui produisent une protéine Bad sont
des cellules caractéristiques du système immunitai-
re, de’ préférence des cellules T.
14. Procédé selon l’une quelconque des revendications
9 à 13, dans lequel la présence ou l’absence de ra-
deaux lipidiques est visualisée par microscopie con-
focale.
15. Procédé selon l’une quelconque des revendications
9 à 13, dans lequel la présence ou l’absence de ra-
deaux lipidiques est déterminée par les étapes
suivantes : 
i) récupérer les cellules cultivées incubées avec
ledit composé candidat et remettre en suspen-
sion lesdites cellules dans un tampon adapté à
un fractionnement sous-cellulaire, tel qu’un tam-
pon de gradient de saccharose ;
ii) ultracentrifuger les cellules fractionnées ; et
iii) récupérer la fraction sous-cellulaire qui de-
vrait contenir des radeaux lipidiques ;
iv) déterminer si la fraction sous-cellulaire récu-
pérée contient un ganglioside et/ou une(des)
molécule(s) associée(s) à des radeaux lipidi-
ques.
16. Procédé selon la revendication 14 ou 15, dans lequel
la présence ou l’absence de radeaux lipidiques est
déterminée par l’utilisation d’un marqueur qui recon-
naît spécifiquement un ganglioside ou une molécule
associée à des radeaux.
17. Procédé selon la revendication 16, dans lequel ledit
marqueur est choisi parmi la sous-unité B de la toxine
cholérique (CTx), un anticorps anti- Bad et un anti-
corps anti-Lck.
18. Procédé selon l’une quelconque des revendications
1 à 17, dans lequel lesdites cellules sont des cellules
de mammifère.
19. Procédé selon l’une quelconque des revendications
1 à 18, dans lequel lesdites conditions non apopto-
tiques sont des conditions prolifératives.
20. Procédé selon l’une quelconque des revendications
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9 à 13 ou 15 à 18 et 19, dans lequel ledit milieu de
croissance comprend au moins une cytokine ou un
facteur de croissance nécessaire pour maintenir des
conditions de croissance prolifératives.
21. Procédé selon l’une quelconque des revendications
11, 17 et 20, dans lequel les conditions apoptotiques
de l’étape c) sont obtenues en privant les cellules de
ladite cytokine ou dudit facteur de croissance.
22. Procédé selon la revendication 20, dans lequel la
cytokine ou le facteur de croissance nécessaire pour
maintenir des conditions de croissance prolifératives
est une interleukine, de préférence choisie parmi l’IL-
4, l’IL-2 et l’IL-9, ou un mélange de celles-ci.
23. Utilisation d’un composé susceptible de reconstituer
des radeaux lipidiques pour la préparation d’un mé-
dicament destiné au traitement de troubles induits
par ou associés à une régulation défectueuse de la
mort cellulaire résultant en une augmentation anor-
male de la mort cellulaire ou de toute pathologie spé-
cifique dans laquelle la mort cellulaire peut être au
moins une partie de la thérapie.
24. Utilisation selon la revendication 23, dans laquelle
ladite régulation défectueuse affecte des cellules qui
produisent la protéine Bad.
25. Utilisation selon la revendication 24, dans laquelle
ladite régulation défectueuse affecte des cellules du
système immunitaire.
26. Utilisation selon la revendication 23, dans laquelle
une pathologie résultant en une augmentation anor-
male de la mort cellulaire est une maladie associée
à la sénescence, la maladie neurodégénérative
d’Alzheimer, le SIDA, la mort cellulaire ischémique
ou la cicatrisation.
27. Utilisation selon l’une quelconque des revendica-
tions 23 et 26, dans laquelle un composé susceptible
de reconstituer des radeaux lipidiques est l’édelfo-
sine.
28. Procédé in vitro pour la détection d’une régulation
défectueuse de l’apoptose dans un échantillon de
cellules d’un individu, ledit procédé comprenant la
détermination de la présence ou de l’absence de ra-
deaux lipidiques dans lesdites cellules, dans lequel
l’absence desdits radeaux lipidiques est indicatrice
d’une régulation défectueuse de l’apoptose.
29. Procédé selon la revendication 28, dans lequel les-
dites cellules sont des cellules du système immuni-
taire d’un individu affecté par une maladie lympho-
proliférative.
30. Procédé selon l’une quelconque des revendications
28 à 29, dans lequel la présence ou l’absence de
radeaux lipidiques est déterminée en détectant la
présence ou l’absence d’une protéine pro-apoptoti-
que ou anti-apoptotique qui est connue pour être si-
tuée dans des radeaux lipidiques dans des condi-
tions non apoptotiques de cellules.
31. Procédé selon la revendication 30, dans lequel une
protéine pro-apoptotique connue pour être située
dans des radeaux lipidiques dans des conditions non
apoptotiques est la protéine Bad.
32. Utilisation d’un composé approprié pour détecter la
présence de radeaux lipidiques, dans le procédé de
détection in vitro selon l’une quelconque des reven-
dications 28 à 31.
33. Utilisation selon la revendication 32, dans laquelle
un composé approprié pour détecter la présence de
radeaux lipidiques est un composé qui reconnaît
spécifiquement la protéine Bad, la protéine Lck ou
le ganglioside GM1.
34. Utilisation selon la revendication 33, dans laquelle
ledit composé est choisi parmi la sous- unité B de la
toxine cholérique (CTx), un anticorps anti-Bad et un
anticorps anti- Lck.
35. Utilisation d’un composé susceptible de moduler la
localisation dans des radeaux d’une protéine de la
famille Bcl-2 pour la préparation d’un médicament
destiné au traitement de troubles induits par ou as-
sociés à une régulation défectueuse de la mort cel-
lulaire ou de toute pathologie spécifique dans laquel-
le la mort cellulaire peut être au moins une partie de
la thérapie.
36. Utilisation selon la revendication 35, dans laquelle
ledit composé favorise la ségrégation d’une protéine
de la famille Bcl-2 depuis des radeaux lipidiques.
37. Utilisation selon la revendication 35, dans laquelle
ledit composé favorise la localisation d’une protéine
de la famille Bcl-2 dans des radeaux lipidiques.
38. Procédé in vitro pour la détection d’une régulation
défectueuse de l’apoptose dans un échantillon de
cellules d’un individu, ledit procédé comprenant la
détermination de la présence ou de l’absence de ra-
deaux lipidiques dans lesdites cellules, dans lequel
la présence d’un grand nombre de radeaux lipidi-
ques en comparaison de cellules normales est indi-
catrice d’une régulation défectueuse de l’apoptose.
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